FDA Announces Recall of Apple Juice in 28 States Due to Potential Mold Contamination
According to the U.S. Food and Drug Administration (FDA), 7,234 cases of Martinelli's apple juice are subject to recall due to potential mold contamination.
A single lot of 10-ounce glass bottles of Martinelli's Apple Juice (sold in four-packs) may contain elevated levels of patulin, a naturally occurring mycotoxin produced by mold and fungus that may be present in apples. Long-term exposure to patulin can cause nausea, gastrointestinal issues, vomiting, and other side effects.
While S. Martinelli & Company originally issued the voluntary recall on March 18, the FDA posted the Class II classification notice on April 22. A Class II recall is the second most severe type of recall, indicating that the product may cause "temporary" or "reversible" health consequences.
The recalled juice was sold in four-packs of round, clear glass 10-ounce bottles with white metal screw top lids. It can be further identified with the following information:
UPC: 0 41244 04102 2
Best By Date: Dec. 5, 2026
Affected cases were distributed to stores in 28 states: Alabama, Arkansas, Arizona, California, Connecticut, Delaware, Florida, Georgia, Iowa, Illinois, Indiana, Kansas, Kentucky, Louisiana, Michigan, Missouri, Mississippi, North Carolina, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, South Carolina, Texas, Utah, Virginia, and Wisconsin.
A full list of pallet/batch numbers can be found on the FDA recall notice page.
While the FDA doesn't list specific instructions, it is typically advised that if you have the recalled Martinelli's Apple Juice, you should not consume it. Instead, dispose of it or return it to the original place of purchase for a refund. Contact your healthcare provider if you have additional concerns regarding patulin exposure.
Consumers with questions about the recall can contact S. Martinelli at 1-800-622-1868.Popular Costco Product Recalled for Wood Contamination
USDA Announces Health Alert for Pork Sold at Aldi Due to Potential Metal Contamination
USDA Issues Health Alert for Multiple Brands of Soup—Including Campbell's—for Potential Wood ContaminationRead the original article on ALLRECIPES
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.
Funding supports pivotal Phase 3 trial for sovateltide, a potential first-in-class therapy that could transform the treatment of acute cerebral ischemic stroke WILLOWBROOK, Ill., June 11, 2025 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz" or the "Company"), a late-stage biopharmaceutical company developing innovative therapies for unmet medical needs in critical care and neurology, has announced a $25 million equity investment from Sun Pharmaceutical Industries Limited (Reuters: Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies), one of the world's leading pharmaceutical companies. This strategic investment brings Sun Pharma's total commitment in Pharmazz to $40 million (including a previous $15 million equity investment). 'We believe sovateltide has the potential to redefine the treatment of ischemic stroke, which has not seen a new FDA approved non-thrombolytic therapy in over 30 years. This investment means we are now fully funded to complete our pivotal Phase 3 study and execute on our mission to make this first in class therapy available to stroke patients,' said Emeritus Prof. Anil Gulati, CEO and Founder of Pharmazz. 'We deeply value Sun Pharma's continued partnership, which strengthens our ability to bring our therapies to patients worldwide.' The new funding will provide Pharmazz with the capital required to complete the pivotal U.S. Phase 3 clinical trial of sovateltide (known as Tycamzzi® and Tyvalzi™ in international markets), its lead drug candidate for treating acute cerebral ischemic stroke. Dr. Neil Marwah, President of Pharmazz, added, 'This investment gives us the operational runway to execute a complex, multi-country clinical trial and scale the company responsibly as we prepare for a potential public offering. We are thrilled to strengthen our partnership with Sun Pharma, whose continued support reflects deep confidence in our platform and our ability to execute.' Phase 3 Trial of Sovateltide for Stroke Covered by Special Protocol Assessment Sovateltide is a first-in-class endothelin-B receptor agonist to treat acute cerebral ischemic stroke that can be administered up to 24 hours after the onset of symptoms. Pharmazz has received agreement from the US Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the study design and statistical analysis plan of its Phase 3 clinical trial of sovateltide for the treatment of acute cerebral ischemic stroke patients. Pharmazz is initiating the Phase 3 RESPECT-ETB ( ID: NCT05691244) trial at 65 sites in the US, Germany, Spain, and the UK, designed to enroll 514 stroke patients. The primary endpoint is the proportion of patients demonstrating functional independence post-stroke, defined as a modified Rankin Scale (mRS) score of 0–2 at 90 days after stroke onset. Commercially Approved in India: Early Validation from 60,000+ patients Sovateltide was approved in 2023 in India and marketed by Sun Pharma under the brand name Tyvalzi™, offering compelling proof of concept for global commercialization. In a randomized, placebo-controlled, multicenter clinical trial conducted in 158 cerebral ischemic stroke patients conducted in India, the product was shown to be well tolerated and effective in improving neurological outcomes when administered within 24 hours of stroke symptoms. Patients on Sovateltide were 22.7% more likely to achieve functional independence at 90 days (as measured by mRS score 0–2; p=0.0045) Sovateltide delivered a 17.1% higher rate of favorable National Institutes of Health Stroke Scale (NIHSS) scores (p=0.0024) The ordinal shift in mRS and NIHSS score between control and sovateltide groups was favorable towards sovateltide across the entire range. Results represent the first statistically significant clinical data in stroke in 30 years, since the introduction of alteplase (tPA) Over 60,000 patients treated to date since commercial launch in India Targeting a Multibillion-Dollar Market with a Broader Therapeutic Window Stroke remains one of the leading causes of disability and death globally, with over 7 million ischemic strokes annually. Today, fewer than 15% of patients receive approved interventions, largely due to their narrow treatment window and strict eligibility criteria. Sovateltide's 24-hour dosing window and broader eligibility could expand access—particularly for underserved populations—and position it as a major advance in acute stroke care. If successful in Phase 3 and subsequently approved, sovateltide has strong commercial potential and is expected to be a foundational product in the Pharmazz emerging neurology franchise. About Sovateltide Sovateltide is a first-in-class drug to treat acute cerebral ischemic stroke, a condition in which the loss of blood supply to the brain prevents brain tissue from receiving oxygen and nutrients, resulting in potential brain damage, neurological deficits, or death. Sovateltide is unique because its action site is the neural progenitor cells. Sovateltide promotes neurovascular remodeling by forming new neurons (neurogenesis) and blood vessels (angiogenesis). Sovateltide also protects neural mitochondria and enhances their biogenesis. About Pharmazz, Inc. Pharmazz is a privately held company developing novel products in critical care medicine. Pharmazz, Inc. obtained marketing authorization for two of its first-in-class drug molecules, centhaquine and sovateltide, for hypovolemic shock and ischemic stroke, respectively, in India. In addition, the US Food and Drug Administration (FDA) has approved two phase III INDs for centhaquine as an agent for hypovolemic shock and sovateltide for cerebral ischemic stroke. Additional information may be found on the Company's website, About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050): Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. and global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and oncodermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit Disclaimer: Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. Contacts: Pharmazz, Inc. Investors Kabir Marwah MediaShruti Gulati Tel +1 630 780 6087 Tel +1 630 780 6087 E mail E mail produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
Buzz Feed
an hour ago
- Buzz Feed
Experts Explain Why European Food Is Better For You
We've all been there. You go abroad — or have a friend who did (let's call her Rebecca) — and suddenly she's unbearable. She won't stop talking about Bar-the-lona and how the tomatoes just tasted better, how walking everywhere changed her life, how pasta in Rome doesn't even count as carbs, and how Americans 'just don't get it.' But as insufferable as she may be, Rebecca might actually have a point — especially when it comes to the food. At some point, a lot of us come back from Europe feeling…better. Healthier. Lighter. More alive. Maybe it's the slower pace, the extra steps on cobblestone streets, the two-day vacationship with a man named Matteo, or the fact that your nervous system finally got a break from interpreting every period in a Slack message as a personal attack. Or maybe it's because you inhaled bread, cheese, wine, and pasta daily, and somehow came back feeling leaner. So what gives? Is the food actually better over there, or are we all just drunk on Aperol and vacation delusion? Dr. Sandy Ziya, a functional medicine physician, says food quality in Europe really does make a difference. One of the biggest culprits behind that post-vacation glow? A break from ultra-processed foods. 'In my experience, when my patients visit Europe, they do feel healthier,' she says. 'There are many aspects of the processed food and the preparation of food that contribute to that.' And here's the thing: ultra-processed foods aren't just heavily refined — they're also loaded with additives, preservatives, and lab-made ingredients you can't pronounce. That's where the real trouble starts. 'In Europe, food colorings like Red Dye 3 and additives such as glyphosate [yep, the same stuff in Roundup weed killer] are prohibited,' says Dr. Ziya. That's because the European Food Safety Authority requires additives to be proven safe before they're approved. In the U.S., the FDA is a little looser. Instead, we've got the GRAS loophole — short for 'Generally Recognized As Safe.' It allows companies to add ingredients based on expert opinion or historical use, which sounds okay in theory, until you remember that food companies have literally paid scientists to claim cereal was a health food. So, yeah — 'safe' is doing a lot of heavy lifting here. Hey, you! Wanna cook easy recipes in step-by-step mode? Download the free Tasty app right now. Dr. Supriya Rao, a gastroenterologist, explains that all those additives and preservatives can do more than just make you feel sluggish — they can mess with your gut on a cellular level. 'Some common American additives (like carrageenan, polysorbate 80, and certain oils) may alter gut bacteria or increase permeability and increase cytokine production, contributing to inflammation and digestive issues over time,' she says. Zooming out, Dr. Rao adds that the broader issue is how the Standard American Diet stacks all of this together. 'It's full of processed foods, sugary drinks, fast foods, red meat, alcohol, and additives. Eating like this consistently drives chronic inflammation, insulin resistance, gut dysbiosis, weight gain, and more — all of which are foundational triggers for diseases like type 2 diabetes, autoimmune disorders, and cardiovascular issues.' So yes, our food might be slowly killing us. But, hey, at least it's convenient, right? Here's the thing: It's not about guilt-tripping you into growing your own kale or never eating a gas station Snickers again. It's about awareness. Because once you know what you're up against, you can actually do something about it. 'Most people don't even know they're consuming ultra-processed food at every meal,' says Dr. Ziya. 'But the lack of satiety — that never-full feeling — is a major clue. Processed foods hijack your hunger cues.' If you've ever eaten a full bag of Doritos and still felt snacky, you know what she's talking about. So what can we do? Short of moving to a seaside village in Sicily, eating tomatoes grown out of your own garden, and making your own pasta with locally milled flour (honestly, tempting), here are a few real-world tips: — Read ingredient lists. If it has 32 ingredients and you can't pronounce half of them, maybe skip it.— Prioritize organic when possible. Yes, it's more expensive. But when you can, do it. Especially for produce and animal products.— Look for 'banned in Europe' ingredients. If it's banned over there and allowed here, consider it a red flag (not a sexy red flag either).— Cook more at home. Even just a couple of meals a week can help cut down on additives.— Follow the 80/20 rule. You don't have to eat clean all the time; just try to make it your maybe, just maybe, we start holding food manufacturers and government regulators accountable: lobby for better labeling, ask questions, and vote with your fork. Because right now, Europe isn't winning the food game by accident. They're winning because they actually care about public health. Wild, right? TL;DR: Yes, European food is generally healthier. Their food safety standards are stricter, and their ingredient lists are shorter. Your vacation glow isn't all in your head — your gut, your sleep, and your mood probably did improve because of what (and how) you ate. But you don't have to hop on a plane every time you want to feel better. Start small. Stay curious. And hey, if you happen to meet a hot man while shopping for organic zucchini in Trader Joe's, that's just a bonus. Thinking of cooking at home tonight? Download the free Tasty app, where you can follow step-by-step instructions for over 7,500 recipes — no subscription required.
Yahoo
an hour ago
- Yahoo
SONU Band by SoundHealth Receives Pediatric FDA Approval
SoundHealth has developed the world's first FDA-approved, wearable device for children 12 and up that offers a drug-free, safe solution for treating nasal congestion and allergies. SAN FRANCISCO, June 11, 2025--(BUSINESS WIRE)--SoundHealth, a medical technology company harnessing the power of artificial intelligence and medical science to improve patient outcomes, announced it received United States Food and Drug Administration (FDA) approval for pediatric use of its groundbreaking SONU Band. SONU is the world's first FDA De Novo authorized, AI-enabled, wearable medical device for at-home treatment of moderate to severe nasal congestion due to allergic and non-allergic rhinitis. This expanded approval makes SONU the first FDA-approved, drug-free solution for nasal congestion and allergies in children ages 12 and up, providing a safe alternative to pharmaceutical treatments. "SONU offers a promising new option for children struggling with chronic nasal congestion. As a non-invasive, drug-free solution, it addresses a significant need among families looking for safe, effective alternatives to traditional therapies—particularly those involving steroids or medications with side effects," said Dr. Alan Greene, Adjunct Professor of Pediatrics, Stanford University; Principal Investigator. Clinically proven to be fast-acting and effective, over 80 percent of SONU patients reported improvement in their nasal symptoms. SONU represents a brand-new category of safe and rapid relief therapies for nasal congestion and spares patients from the side effects commonly associated with other treatment options. "Nasal congestion and allergies don't have to be life-altering," said Dr. Paramesh Gopi, founder and CEO of SoundHealth. "Our team of scientists, engineers and medical professionals has truly revolutionized respiratory health with AI-powered sound therapy. We are thrilled to now be able to offer relief from congestion to children and will continue to work toward helping people breathe better." SONU is easy, convenient and pleasant to use for patients. Using SoundHealth's proprietary AI technology, the SONU app scans the patient's face using a smartphone and creates a digital map of their sinuses, calculating their optimal resonant frequencies. Following the initial one-time scan, the patient simply places the SONU Band around their head, turns it on and the band delivers frequencies tailored to the patient based on the app's calculations. The science behind SONU: SONU uses acoustic vibrational energy to provide personalized relief for nasal congestion. The band produces resonant sound waves that gently vibrate the nasal cavity. These micro vibrations help reduce swelling, open nasal passages and drain healthy mucus. Acoustic vibration associated with humming has been shown to decrease symptoms of nasal congestion, possibly through modulation of autonomic inputs to the nasal mucosa or through nitric oxide activity, which may in turn exert a decongestant and anti-inflammatory effect on the nasal passages. Using personalized, relaxing sound waves, SONU provides relief of nasal symptoms in 15 minutes or less. SONU is the only FDA-approved device equivalent to or better than the leading nasal steroid spray, calming down symptoms of allergies, inflammation and congestion. For more information, please visit About SoundHealth SoundHealth is a medical technology company that harnesses the power of artificial intelligence and medical science to improve respiratory and mental health. The SoundHealth team consists of experienced medical professionals, data scientists and engineers who are passionate about improving healthcare. Visit View source version on Contacts Jared@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
